Compare Akamai Technologies, Inc. (AKAM) vs Oscar Health Inc (OSCR) Price & Performance

Akamai Technologies (AKAM) trades at $114.37, up 1.06% on the day but down significantly from its 26-year high of $165.45 in May 2026. The stock faces a bearish technical signal despite recent earnings beats. Revenue growth has slowed to 5% annually, with net income margin declining from 14.47% in 2022 to 10.74% in 2025. The company continues strategic moves in cybersecurity, completing the LayerX acquisition and expanding its NVIDIA partnership for AI security.

While analyst consensus remains positive with a $170.20 price target, near-term headwinds include declining profitability, high valuation multiples, and competitive pressures. The stock's current pullback presents a potential entry point for long-term investors believing in its cybersecurity and cloud computing positioning, though execution risks and margin compression require monitoring.

Oscar Health (OSCR) trades at $31.44, down 2.3% on the day but showing strong technical momentum with a bullish moving average signal. The company reported a significant Q1 2026 earnings beat with EPS of $2.07 versus $1.21 expected, though full-year 2025 results showed a net loss of $443 million. Revenue growth remains robust, projected to increase from $11.7 billion in 2025 to $13.3 billion in 2026, while operating cash flow improved substantially.

The outlook is mixed: strong revenue growth and positive cash flow support upside potential, but persistent net losses and negative ROE pose fundamental risks. Analyst consensus is cautious with a $22.50 price target below current levels, indicating skepticism about sustainability despite recent operational improvements.